Literature DB >> 17597334

Interleukin-18 as a mediator of systemic juvenile idiopathic arthritis.

Marija Jelusić1, Ivan Kresimir Lukić, Lana Tambić-Bukovac, Klara Dubravcić, Ivan Malcić, Igor Rudan, Drago Batinić.   

Abstract

The objective of this report is to explore the balance between serum and synovial fluid levels of interleukin (IL)-18 in children with juvenile idiopathic arthritis (JIA). Blood samples were obtained from 81 children with JIA and 18 control children. Synovial fluid samples were collected from 16 children with oligoarticular JIA. Concentrations of IL-18 were determined using commercial kit. Patients with systemic JIA had higher serum levels of IL-18 than patients with other forms of JIA or control children, both during the active (median, range: 6,240, 1,600-78,750 pg/ml) and inactive (1,615, 513-3,270 pg/ml) phase of disease [analysis of variance (ANOVA), P<0.05). Levels of IL-18 in sera of children with oligoarticular JIA (255, 89-4,342 pg/ml) were similar to the respective synovial fluid levels (217, 89-1,245 pg/ml). Serum levels of IL-18 were proportional to the erythrocyte sedimentation rate and levels of C-reactive protein, but inversely proportional to the haemoglobin levels. IL-18 appears to be an important mediator of systemic JIA, while it seems of a lesser relevance in pathogenesis of other JIA forms. Therefore, inhibition of IL-18 might be a base for a successful biological therapy for systemic JIA.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17597334     DOI: 10.1007/s10067-006-0474-0

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  13 in total

Review 1.  Interleukin-18 as a potential target in inflammatory arthritis.

Authors:  J A Gracie
Journal:  Clin Exp Immunol       Date:  2004-06       Impact factor: 4.330

2.  Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis.

Authors:  Carol A Wallace; Nicolino Ruperto; Edward Giannini
Journal:  J Rheumatol       Date:  2004-11       Impact factor: 4.666

Review 3.  Inflammation in juvenile idiopathic arthritis.

Authors:  Kathleen E Sullivan
Journal:  Pediatr Clin North Am       Date:  2005-04       Impact factor: 3.278

4.  Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997.

Authors:  R E Petty; T R Southwood; J Baum; E Bhettay; D N Glass; P Manners; J Maldonado-Cocco; M Suarez-Almazor; J Orozco-Alcala; A M Prieur
Journal:  J Rheumatol       Date:  1998-10       Impact factor: 4.666

Review 5.  Do chemokines spark autoimmunity in juvenile and adult rheumatic disease?

Authors:  Harald Mangge; Jelena Vojinovic; Konrad Schauenstein
Journal:  Immunobiology       Date:  2002-10       Impact factor: 3.144

Review 6.  Role of interleukin 15 and interleukin 18 in inflammatory response.

Authors:  F Y Liew; I B McInnes
Journal:  Ann Rheum Dis       Date:  2002-11       Impact factor: 19.103

Review 7.  Biologic therapies for juvenile arthritis.

Authors:  N Wilkinson; G Jackson; J Gardner-Medwin
Journal:  Arch Dis Child       Date:  2003-03       Impact factor: 3.791

8.  Interferon-gamma:interleukin 4 ratios and associated type 1 cytokine expression in juvenile rheumatoid arthritis synovial tissue.

Authors:  Michael P Scola; Susan D Thompson; Hermine I Brunner; Monica K Tsoras; David Witte; Marc A Van Dijk; Alexei A Grom; Murray H Passo; David N Glass
Journal:  J Rheumatol       Date:  2002-02       Impact factor: 4.666

Review 9.  Interleukin-18.

Authors:  J Alastair Gracie; Susan E Robertson; Iain B McInnes
Journal:  J Leukoc Biol       Date:  2003-02       Impact factor: 4.962

10.  CD4+CD25bright regulatory T cells actively regulate inflammation in the joints of patients with the remitting form of juvenile idiopathic arthritis.

Authors:  Ismé M de Kleer; Lucy R Wedderburn; Leonie S Taams; Alka Patel; Hemlata Varsani; Mark Klein; Wilco de Jager; Gisela Pugayung; Francesca Giannoni; Ger Rijkers; Salvatore Albani; Wietse Kuis; Berent Prakken
Journal:  J Immunol       Date:  2004-05-15       Impact factor: 5.422

View more
  14 in total

Review 1.  What do cytokine profiles tell us about subsets of juvenile idiopathic arthritis?

Authors:  Rolando Cimaz; Davide Moretti; Ilaria Pagnini; Achille Marino; Luca Cantarini; Gabriele Simonini
Journal:  Curr Rheumatol Rep       Date:  2012-04       Impact factor: 4.592

2.  Distribution of circulating cells in systemic juvenile idiopathic arthritis across disease activity states.

Authors:  Claudia Macaubas; Khoa Nguyen; Chetan Deshpande; Carolyn Phillips; Ariana Peck; Tzielan Lee; Jane L Park; Christy Sandborg; Elizabeth D Mellins
Journal:  Clin Immunol       Date:  2009-10-29       Impact factor: 3.969

3.  IL-18 as a biomarker linking systemic juvenile idiopathic arthritis and macrophage activation syndrome.

Authors:  Shima Yasin; Ndate Fall; Rachel A Brown; Maggie Henderlight; Scott W Canna; Charlotte Girard-Guyonvarc'h; Cem Gabay; Alexei A Grom; Grant S Schulert
Journal:  Rheumatology (Oxford)       Date:  2020-02-01       Impact factor: 7.580

Review 4.  From bench to bedside and back again: translational research in autoinflammation.

Authors:  Dirk Holzinger; Christoph Kessel; Alessia Omenetti; Marco Gattorno
Journal:  Nat Rev Rheumatol       Date:  2015-06-16       Impact factor: 20.543

5.  Plasma profiles in active systemic juvenile idiopathic arthritis: Biomarkers and biological implications.

Authors:  Xuefeng B Ling; Jane L Park; Tanya Carroll; Khoa D Nguyen; Kenneth Lau; Claudia Macaubas; Edward Chen; Tzielan Lee; Christy Sandborg; Diana Milojevic; John T Kanegaye; Susanna Gao; Jane Burns; James Schilling; Elizabeth D Mellins
Journal:  Proteomics       Date:  2010-11-23       Impact factor: 3.984

Review 6.  Overview of the IL-1 family in innate inflammation and acquired immunity.

Authors:  Charles A Dinarello
Journal:  Immunol Rev       Date:  2018-01       Impact factor: 12.988

Review 7.  Interleukin-18 and IL-18 binding protein.

Authors:  Charles A Dinarello; Daniela Novick; Soohyun Kim; Gilles Kaplanski
Journal:  Front Immunol       Date:  2013-10-08       Impact factor: 7.561

Review 8.  Review of biomarkers in systemic juvenile idiopathic arthritis: helpful tools or just playing tricks?

Authors:  Faekah Gohar; Christoph Kessel; Miha Lavric; Dirk Holzinger; Dirk Foell
Journal:  Arthritis Res Ther       Date:  2016-07-13       Impact factor: 5.156

Review 9.  New frontiers in the treatment of systemic juvenile idiopathic arthritis.

Authors:  Susan Canny; Elizabeth Mellins
Journal:  F1000Res       Date:  2017-06-22

10.  Challenges in the management of juvenile idiopathic arthritis with etanercept.

Authors:  Clare E Pain; Liza J McCann
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.